There have been few case reports to date documenting successful responses to ruxolitinib in Ph-like ALL, with only one report in JAK2-mutant Ph-like ALL (Mayfield et al., 2017) and four reports in JAK2r Ph-like ALL (Ding et al., 2018; Chen X. et al., 2019; Chen et al., 2022; Rizzuto et al., 2022). Here, JAK2 is linked to acute lymphoblastic leukemia.